JP2013522363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522363A5 JP2013522363A5 JP2013501347A JP2013501347A JP2013522363A5 JP 2013522363 A5 JP2013522363 A5 JP 2013522363A5 JP 2013501347 A JP2013501347 A JP 2013501347A JP 2013501347 A JP2013501347 A JP 2013501347A JP 2013522363 A5 JP2013522363 A5 JP 2013522363A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridyl
- compound according
- halo
- thienyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 46
- 125000001475 halogen functional group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- -1 4-furyl Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000027520 Somatoform disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000027753 pain disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- KNOYHJOPRUTPSQ-QHCPKHFHSA-N (4s)-5-amino-5-oxo-4-[3-[4-(4-phenylphenyl)phenyl]propanoylamino]pentanoic acid Chemical compound C1=CC(CCC(=O)N[C@@H](CCC(O)=O)C(=O)N)=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 KNOYHJOPRUTPSQ-QHCPKHFHSA-N 0.000 claims description 2
- 208000017194 Affective disease Diseases 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000000648 anti-parkinson Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000009245 menopause Effects 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000003402 opiate agonist Substances 0.000 claims description 2
- 239000003401 opiate antagonist Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000001457 vasomotor Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 0 *c(c(*)c1*)c(*)c(*)c1OCC1/C=C/C/C=C/CC1C1CCNCC1 Chemical compound *c(c(*)c1*)c(*)c(*)c1OCC1/C=C/C/C=C/CC1C1CCNCC1 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31609010P | 2010-03-22 | 2010-03-22 | |
| US61/316,090 | 2010-03-22 | ||
| PCT/US2011/029138 WO2011119461A1 (en) | 2010-03-22 | 2011-03-21 | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522363A JP2013522363A (ja) | 2013-06-13 |
| JP2013522363A5 true JP2013522363A5 (https=) | 2014-02-13 |
| JP5769348B2 JP5769348B2 (ja) | 2015-08-26 |
Family
ID=44211953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501347A Expired - Fee Related JP5769348B2 (ja) | 2010-03-22 | 2011-03-21 | １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8530663B2 (https=) |
| EP (1) | EP2550252B1 (https=) |
| JP (1) | JP5769348B2 (https=) |
| ES (1) | ES2543064T3 (https=) |
| WO (1) | WO2011119461A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592543A (en) | 2008-11-14 | 2013-02-22 | Theravance Inc | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
| US8778949B2 (en) * | 2010-01-11 | 2014-07-15 | Theravance Biopharma R&D Ip, Llc | 1-(2-phenoxymethylphenyl)piperazine compounds |
| WO2013064883A1 (en) | 2011-10-31 | 2013-05-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
| JP2022519535A (ja) * | 2019-01-31 | 2022-03-24 | イデアヤ、バイオサイエンシズ、インコーポレイテッド | Ｄｎａポリメラーゼシータ阻害剤としてのヘテロアリールメチレン誘導体 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| DE2549999A1 (de) * | 1975-11-07 | 1977-05-12 | Boehringer Mannheim Gmbh | Piperidin-derivate und verfahren zu ihrer herstellung |
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| US4179563A (en) * | 1978-05-19 | 1979-12-18 | Warner-Lambert Company | 3-Aryloxy-substituted-aminopyridines and methods for their production |
| US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| EP0190496A3 (en) | 1984-12-13 | 1987-05-27 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
| DE3541097A1 (de) * | 1985-11-21 | 1987-05-27 | Miles Lab | Verwendung von thiophenen als ph indikatoren insbesondere in einem nicht-enzymatischen glukosetest |
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| DE3835291A1 (de) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
| GB9324018D0 (en) * | 1993-11-23 | 1994-01-12 | Merck Sharp & Dohme | Therapeutic agents |
| US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
| US6630504B2 (en) * | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
| US7294637B2 (en) * | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| WO2004017977A2 (en) * | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
| NZ540891A (en) * | 2003-04-04 | 2008-07-31 | Lundbeck & Co As H | 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| MXPA05013960A (es) * | 2003-06-17 | 2006-02-24 | Pfizer | Nuevos compuestos. |
| JP2007517855A (ja) * | 2004-01-13 | 2007-07-05 | ファイザー インコーポレイテッド | セロトニン及びノルアドレナリン再取込み阻害剤としての活性を示すピペラジン誘導体 |
| EP1725518A1 (en) * | 2004-03-05 | 2006-11-29 | Eli Lilly And Company | Pharmaceutical compounds |
| JP4185154B2 (ja) * | 2004-04-30 | 2008-11-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害治療用の置換モルホリン化合物 |
| JP4906715B2 (ja) * | 2004-05-08 | 2012-03-28 | ニューロジェン・コーポレーション | ４，５−ジ置換−２−アリールピリミジン類 |
| WO2008023258A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
| US8026257B2 (en) * | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| TW200918521A (en) * | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
| WO2009081259A1 (en) * | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
| CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
| NZ592543A (en) * | 2008-11-14 | 2013-02-22 | Theravance Inc | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds |
| ES2440000T3 (es) * | 2009-05-08 | 2014-01-27 | Tetraphase Pharmaceuticals, Inc. | Compuestos de 8-aza-tetraciclina |
-
2011
- 2011-03-21 JP JP2013501347A patent/JP5769348B2/ja not_active Expired - Fee Related
- 2011-03-21 EP EP20110714878 patent/EP2550252B1/en not_active Not-in-force
- 2011-03-21 US US13/052,273 patent/US8530663B2/en not_active Expired - Fee Related
- 2011-03-21 ES ES11714878.3T patent/ES2543064T3/es active Active
- 2011-03-21 WO PCT/US2011/029138 patent/WO2011119461A1/en not_active Ceased
-
2013
- 2013-08-09 US US13/963,255 patent/US20130324550A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521994A5 (https=) | ||
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2014508811A5 (https=) | ||
| JP2023508469A5 (https=) | ||
| WO2008035358A3 (en) | Process for preparing dapoxetine | |
| CA2713025A1 (en) | Kappa selective opioid receptor antagonist | |
| JP2011529069A5 (https=) | ||
| BR112014005389A8 (pt) | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal | |
| CY1110075T1 (el) | Παρασκευη(2r,3r)-3-(3-μεθοξυφαινυλ)-ν,ν,2-τριμεθυλοπενταναμινης | |
| JP2014500861A5 (https=) | ||
| IN2014KN00948A (https=) | ||
| AR084174A1 (es) | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica | |
| JP2012521428A5 (https=) | ||
| EA201101308A1 (ru) | Применение ралфинамида для лечения биполярного расстройства | |
| JP2014502641A5 (https=) | ||
| NO20073208L (no) | 4-fenylsubstituerte tetrahydrotsokindiner og anvendelse derav til a blokkere gjenopptak av norepinefrin, dopamin og serotonin | |
| JP2013522363A5 (https=) | ||
| WO2010011811A4 (en) | 3-(phenoxyphenylmethyl)pyrrolidine compounds | |
| MY151211A (en) | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| JP2015502973A5 (https=) | ||
| MX2012000685A (es) | Compuesto de 3-fenoximetilpirrolidina. | |
| JP2014518552A5 (https=) | ||
| JP2012520899A5 (https=) | ||
| MX2007006082A (es) | Tetrahidroisoquinolinas aril- y heteroaril-sustituidas, y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina. | |
| JP2010508245A5 (https=) |